Shots: 

• Danaher to acquire biopharma unit of GE Life Sciences (GE Biopharma)- in all stock transaction making total deal value of $21.4 B. GE Biopharma to receive $21.4B- including $18B in cash and $3B as convertible preferred shares in Danaher
• The focus of the acquisition is to strengthen & advance Danaher's life science portfolio using GE's bioprocessing technologies in developing therapies
• GE Biopharma unit comprises of chromatography hardware- cell culture media- single-use technologies- development instrumentation and service for research and development of drugs in multiple therapy areas. The transaction is expected to close on Q4'19

Ref: Danaher Corporation | Image: Yahoo Finance